fda warning letters compounded semaglutide 2024 2025 Troubling Findings in Study of GLP-1 Compounders FDA warns telehealth companies over

Patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trial, lead investigator Hamlet Gasoyan said in a news release

While diabetes, hypertension, and sleep apnea are well-known risk factors, recent studies have identified a potential association between semaglutide-based GLP-1 medications and NAION

5.7 Hypersensitivity Reactions There have been postmarketing reports of serious hypersensitivity reactions (e.g., angioedema) in patients treated with empagliflozin

They fight inflammation, protect cells from damage, provide benefits to blood vessels, and reduce protein excretion in urine [27]

Most users tolerate this range without gastrointestinal upset, though doses above 5 grams may cause loose stools